首页> 外文期刊>Applied Microbiology and Biotechnology >A combinatorial approach of N-terminus blocking and codon optimization strategies to enhance the soluble expression of recombinant hIL-7 in E-coli fed-batch culture
【24h】

A combinatorial approach of N-terminus blocking and codon optimization strategies to enhance the soluble expression of recombinant hIL-7 in E-coli fed-batch culture

机译:N端封闭和密码子优化策略的组合方法,用于增强大肠杆菌补料分批培养物中重组hIL-7的可溶性表达

获取原文
获取原文并翻译 | 示例
       

摘要

Human interleukin-7 (hIL-7) is a therapeutically important cytokine involved in lymphocyte development and survival. In previous reports, a uniformly poor expression of hIL-7 has been shown in Escherichia coli host with the problem of inclusion body formation. In this study, the role of codon optimization and N-terminus blocking using various solubility enhancer fusion tags was explored to improve its soluble expression. The use of codon optimization strategy improved its expression to 80 +/- 5 mg/L at shake flask level. The utilization of pelB leader sequence resulted in an unprocessed protein in the form of cytoplasmic inclusion bodies with lower expression yields. The N-terminus fusion of small ubiquitin-like modifier (SUMO), thioredoxin (Trx), and NusA tags increased the expression in the range of 90-140 mg/L, where > 90 % of the fusion protein was obtained in soluble form. The fed-batch fermentation of SUMO-tagged hIL-7 protein was optimized at bioreactor level, where a high volumetric product concentration of 2.65 g/L was achieved by controlling the plasmid segregation instability using high antibiotic concentration. The specific product yield (Y-P/X) and volumetric product concentration were 1.38 and 2.55-fold higher compared to batch results, respectively. A preparative scale affinity chromatography resulted in a high recovery yield of 50.6 mg/L with similar to 90 % purity. The conformational property of purified recombinant hIL-7 from CD spectroscopy showed a typical helical structure with 31.5 % alpha-helix and 26.43 % beta-sheet. The biological activity of purified protein was tested using IL-7-dependent murine immature B lymphocyte (2E8) cell line by 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide salt (MTT) assay, where it showed a similar biological activity as standard control.
机译:人白介素7(hIL-7)是一种重要的细胞因子,参与淋巴细胞的发育和存活。在以前的报道中,已经证明在大肠杆菌宿主中hIL-7的表达始终很差,存在包涵体形成的问题。在这项研究中,使用各种溶解度增强剂融合标签探索了密码子优化和N末端封闭的作用,以改善其可溶性表达。密码子优化策略的使用将其在摇瓶水平上的表达提高至80 +/- 5 mg / L。 pelB前导序列的利用导致以细胞质内含体形式存在的未加工蛋白质,具有较低的表达产量。小泛素样修饰剂(SUMO),硫氧还蛋白(Trx)和NusA标签的N端融合蛋白可在90-140 mg / L的范围内增加表达,其中> 90%的融合蛋白以可溶性形式获得。在生物反应器水平上优化了SUMO标签的hIL-7蛋白的分批补料发酵,其中通过使用高抗生素浓度控制质粒分离的不稳定性实现了2.65 g / L的高体积产物浓度。与批处理结果相比,单位产品收率(Y-P / X)和产品体积浓度分别高1.38和2.55倍。制备规模的亲和色谱法得到50.6 mg / L的高回收率,纯度接近90%。来自CD光谱的纯化的重组hIL-7的构象性质显示具有31.5%的α-螺旋和26.43%的β-折叠的典型螺旋结构。使用IL-7依赖的小鼠未成熟B淋巴细胞(2E8)细胞系,通过3-(4,5-二甲基噻唑-2-基)-2,5-二苯基溴化四唑盐(MTT)分析测试纯化蛋白的生物学活性。 ,它显示出与标准对照相似的生物活性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号